Host cell targets in HCV therapy: novel strategy or proven practice? (Q36124729)

12 August 2017

1 reference

title

Host cell targets in HCV therapy: novel strategy or proven practice? (English)

1 reference

12 August 2017

Bert M Klebl

1

1 reference

12 August 2017

Alexander Kurtenbach

2

1 reference

12 August 2017

Kostas Salassidis

3

1 reference

12 August 2017

Henrik Daub

4

1 reference

12 August 2017

Thomas Herget

5

1 reference

12 August 2017

publication date

1 January 2005

1 reference

Antiviral Chemistry & Chemotherapy

12 August 2017

published in

1 reference

12 August 2017

volume

16

1 reference

12 August 2017

issue

2

1 reference

12 August 2017

page(s)

69-90

1 reference

Hepatitis C virus core protein interacts with 14-3-3 protein and activates the kinase Raf-1

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Modulation of cell growth by the hepatitis C virus nonstructural protein NS5A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Replication of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Novel cell culture systems for the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Hepatitis C virus replicons: potential role for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Efficient initiation of HCV RNA replication in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Innate sensing of viruses by toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Tissue-specific functions of individual glutathione peroxidases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Is there a role of glutathione peroxidases in signaling and differentiation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

The development and therapeutic potential of protein kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

The regulation of protein function by multisite phosphorylation--a 25 year update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

High-throughput screening of the yeast kinome: identification of human serine/threonine protein kinases that phosphorylate the hepatitis C virus NS5A protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

The lymphoid system in hepatitis C virus infection: autoimmunity, mixed cryoglobulinemia, and Overt B-cell malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Evaluation of kinase inhibitor selectivity by chemical proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Strategies in the design of antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Antiviral drugs in current clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Functional genomics in virology and antiviral drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

A pilot study of ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Imiquimod and resiquimod as novel immunomodulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Type I interferons: expression and signalization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Current and emerging therapeutic approaches to hepatitis C infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Novel approaches to the treatment of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

The protein kinase activity modulation sites: mechanisms for cellular regulation - targets for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Lack of Protective Immunity Against Reinfection with Hepatitis C Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Identification of unique hepatitis C virus quasispecies in the central nervous system and comparative analysis of internal translational efficiency of brain, liver, and serum variants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Virogenomics: a novel approach to antiviral drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Hepatitis C virus viremia in SCID-->BNX mouse chimera

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

An efficient proteomics method to identify the cellular targets of protein kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Hepatitis C virus NS5A protein modulates cell cycle regulatory genes and promotes cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Regulation of mRNA Translation and Cellular Signaling by Hepatitis C Virus Nonstructural Protein NS5A

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Subversion of Cell Signaling Pathways by Hepatitis C Virus Nonstructural 5A Protein via Interaction with Grb2 and P85 Phosphatidylinositol 3-Kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Intracellular signalling and antiviral effects of interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Characterization of IDN-6556 (3-[2-(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid): a liver-targeted caspase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Hepatitis C virus NS5B protein is a membrane-associated phosphoprotein with a predominantly perinuclear localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Hepatitis C virus NS5A protein is phosphorylated in vitro by a stably bound protein kinase from HeLa cells and by cAMP-dependent protein kinase A-alpha catalytic subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Early clearance of circulating hepatitis C virus enhanced by induction therapy with twice-a-day intravenous injection of IFN-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

The hepatitis C virus (HCV)-Trimera mouse: a model for evaluation of agents against HCV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Virus interference. I. The interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Evaluation of twice-daily administration of interferon-beta for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Ser(2194) is a highly conserved major phosphorylation site of the hepatitis C virus nonstructural protein NS5A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Viruses and interferon: a fight for supremacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Hepatitis C virus NS5A protein is phosphorylated by casein kinase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Protein kinase C-related kinase 2 regulates hepatitis C virus RNA polymerase function by phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Stacking up the armory against viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Ribavirin Induces Error-Prone Replication of GB Virus B in Primary Tamarin Hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Proton conduction through the M2 protein of the influenza A virus; a quantitative, mechanistic analysis of experimental data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

The search for the CD8+ cell anti-HIV factor (CAF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Protection from HIV/AIDS: the importance of innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Phosphorylation of hepatitis C virus core protein by protein kinase A and protein kinase C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

The hepatitis C virus non-structural NS5A protein inhibits activating protein-1 function by perturbing ras-ERK pathway signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

The hepatitis C virus NS5A protein binds to members of the Src family of tyrosine kinases and regulates kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Amantadine in the akinetic-rigid variant of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Transition of care between paediatric and adult gastroenterology. Chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

alpha-Galactosylceramide and novel synthetic glycolipids directly induce the innate host defense pathway and have direct activity against hepatitis B and C viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Hepatitis C virus replication in mice with chimeric human livers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Metabolic complications associated with the use of highly active antiretroviral therapy in HIV-1-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Expression of gastrointestinal glutathione peroxidase is inversely correlated to the presence of hepatitis C virus subgenomic RNA in human liver cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Medicinal chemistry of target family-directed masterkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

1Hepatitis C virus NS5A protein modulates c-Jun N-terminal kinase through interaction with tumor necrosis factor receptor-associated factor 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

An NS3 serine protease inhibitor abrogates replication of subgenomic hepatitis C virus RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Re-treatment with interferon-beta of patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Regulation of PKR and IRF-1 during hepatitis C virus RNA replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Characterization of cell lines carrying self-replicating hepatitis C virus RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Tissue culture and animal models for hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Hepatitis C virus NS5A mediated STAT3 activation requires co-operation of Jak1 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Interferon-alpha2b induction treatment with or without ribavirin in chronic hepatitis C: a multicenter, randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Early events in hepatitis C virus infection of chimpanzees.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Different turnover rate of hepatitis C virus clearance by different treatment regimen using interferon-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

The Hepatitis C virus NS5A protein activates a phosphoinositide 3-kinase-dependent survival signaling cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Dynamics of Subgenomic Hepatitis C Virus Replicon RNA Levels in Huh-7 Cells after Exposure to Nucleoside Antimetabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Nonlinear partial differential equations and applications: Genomic analysis of the host response to hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Mechanisms of action of ribavirin in antiviral therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Hepatitis C therapeutics: current status and emerging strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Novel technologies for studying virus-host interaction and discovering new drug targets for HCV and HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Peginterferon-alpha 2a (40 kDa)/ribavirin combination for the treatment of chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Immunopharmacology of CpG oligodeoxynucleotides and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Hepatitis C virus NS5A and subgenomic replicon activate NF-kappaB via tyrosine phosphorylation of IkappaBalpha and its degradation by calpain protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Identification and characterization of amphiphysin II as a novel cellular interaction partner of the hepatitis C virus NS5A protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

Clinical consequences of hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020501600201

10.1177/095632020501600201

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference